Compare GSK Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DR. DATSONS LABS - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DR. DATSONS LABS GSK PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 51.4 -10.9 - View Chart
P/BV x 10.8 0.2 6,663.3% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 GSK PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
DR. DATSONS LABS
Mar-14
GSK PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs3,595126 2,862.3%   
Low Rs1,25331 4,055.0%   
Sales per share (Unadj.) Rs184.7133.0 138.9%  
Earnings per share (Unadj.) Rs26.30.2 17,342.3%  
Cash flow per share (Unadj.) Rs29.26.6 441.3%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.3128.8 98.1%  
Shares outstanding (eoy) m169.4031.66 535.1%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x13.10.6 2,231.0%   
Avg P/E ratio x92.2516.1 17.9%  
P/CF ratio (eoy) x83.111.8 701.9%  
Price / Book Value ratio x19.20.6 3,158.4%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,6262,477 16,574.9%   
No. of employees `0005.0NA-   
Total wages/salary Rs m5,37256 9,592.9%   
Avg. sales/employee Rs Th6,306.7NM-  
Avg. wages/employee Rs Th1,083.1NM-  
Avg. net profit/employee Rs Th898.0NM-  
INCOME DATA
Net Sales Rs m31,2814,211 742.9%  
Other income Rs m1,02379 1,300.1%   
Total revenues Rs m32,3044,289 753.2%   
Gross profit Rs m6,009569 1,056.8%  
Depreciation Rs m486204 237.8%   
Interest Rs m6430 1.4%   
Profit before tax Rs m6,54013 51,496.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3736 38,901.6%   
Profit after tax Rs m4,4545 92,791.7%  
Gross profit margin %19.213.5 142.2%  
Effective tax rate %36.348.0 75.5%   
Net profit margin %14.20.1 12,489.9%  
BALANCE SHEET DATA
Current assets Rs m20,0616,852 292.8%   
Current liabilities Rs m14,5436,711 216.7%   
Net working cap to sales %17.63.3 526.8%  
Current ratio x1.41.0 135.1%  
Inventory Days Days57161 35.3%  
Debtors Days Days14318 4.4%  
Net fixed assets Rs m14,3433,673 390.5%   
Share capital Rs m1,694317 535.1%   
"Free" reserves Rs m19,7043,761 523.9%   
Net worth Rs m21,3984,078 524.8%   
Long term debt Rs m21,671 0.1%   
Total assets Rs m39,11312,633 309.6%  
Interest coverage x1,091.01.0 105,971.6%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.80.3 239.9%   
Return on assets %11.43.4 331.1%  
Return on equity %20.80.1 17,681.7%  
Return on capital %31.97.7 416.1%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m534964 55.4%   
Fx outflow Rs m7,091607 1,168.0%   
Net fx Rs m-6,557357 -1,837.2%   
CASH FLOW
From Operations Rs m3,9941,345 297.0%  
From Investments Rs m-1,433-2,256 63.5%  
From Financial Activity Rs m-3,584-1,200 298.7%  
Net Cashflow Rs m-1,023-2,111 48.5%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.0 -  
FIIs % 23.8 1.4 1,763.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 94.1 16.4%  
Shareholders   102,036 20,807 490.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 17, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS